Calithera | Targeting Cancer, Differently | Home

Development Pipeline

Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.

Development Pipeline

Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.

Culture

Therapeutic Areas

Recent News

June 23, 2022: Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
June 14, 2022: Calithera Biosciences Announces 1-for-20 Reverse Stock Split
May 17, 2022: Calithera to Present at the H.C. Wainwright Global Investment Conference
May 10, 2022: Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
May 3, 2022: Calithera Biosciences to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022

View All